Monoclonal Antibody Therapeutics

What Infusion Sites, Healthcare Providers, and Patients Need to Know

Monoclonal antibody therapeutics (mAb), including casirivimab/imdevimab and bamlanivimab, can be used to treat eligible non-hospitalized patients who have tested positive for COVID-19 and have mild to moderate symptoms. These treatments mimic your immune system’s response to SARS-CoV-2 (the infection that causes COVID-19) and are available to  eligible patients 12 years and older with a high risk of progressing to severe forms of COVID-19 or being hospitalized. 

HHS/ASPR has purchased supplies of both COVID-19 monoclonal antibody therapeutic products and we are working with state and territorial health departments as well as national healthcare and medical organizations and associations to get casirivimab/imdevimab and bamlanivimab into the hands of healthcare providers quickly, with a focus on areas of the country hardest hit by the pandemic.

​ Information for Infusion Centers Assessing your facility’s capabilities for becoming  an mAb site » Ordering mAb therapeutics » Seeking reimbursement and coverage »

​ Information for Healthcare Providers Understanding how mAbs benefit patients » Educating patients about  mAbs » Determining patient eligibility » ​

​​ Information for Patients Understanding the benefits of mAb therapeutics » Identifying who is eligible for mAb treatment » Finding a treatment center »